CAPLIPOINTCaplin Point Laboratories Ltd.

    Caplin Point Laboratories Q2 FY27 Results: Consolidated Net Profit ₹182 Crore on Total Income of ₹663 Crore

    • Earnings
    • Pharmaceuticals
    A pile of white, orange and green-and-white capsules and tablets with a glass thermometer lying across them.
    Steve Buissinne (stevepb), via Wikimedia Commons (CC0). Illustrative image.

    Caplin Point Laboratories (NSE: CAPLIPOINT) reported consolidated total income of ₹663.13 crore and net profit of ₹182.35 crore for the quarter ended 30 Sep 2026, it said in a filing on 12 Nov 2026. Standalone total income was ₹292.92 crore and standalone net profit ₹130.51 crore.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹663.13 crore, up 17.5% YoY and 3.0% QoQ
    • Net profit and EPS: ₹182.35 crore, up 13.8% YoY; basic EPS ₹23.44
    • Other income: ₹33.29 crore, 5.0% of total income
    • Finance costs: ₹0.22 crore, up from ₹0.16 crore a year earlier

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹292.92 crore, up 25.0% YoY and 10.2% QoQ
    • Net profit and EPS: ₹130.51 crore, up 27.2% YoY; basic EPS ₹17.17
    • Other income: ₹51.04 crore, including ₹15.19 crore dividend from Caplin Point Far East Limited
    • Finance costs: ₹0.06 crore, up from ₹0.05 crore a year earlier

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    663.13564.41+17.5%643.91+3.0%
    182.35160.23+13.8%179.09+1.8%
    EPS, basic (₹)23.4420.32+15.4%23.27+0.7%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    The company's H1 FY27 consolidated total income was ₹1,307.04 crore and profit after tax ₹361.44 crore, per the press release, which says total revenue rose 19.1% YoY and PAT 16.2%.

    The company says it has allocated a capex budget of approximately ₹1,000 crore for investment projects, to be financed solely through internal accruals. Free cash reserves stood at ₹1,534 crore and total liquid assets at ₹2,967 crore as of 30 Sep 2026, according to the press release.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    292.92234.40+25.0%265.74+10.2%
    130.51102.59+27.2%120.38+8.4%
    EPS, basic (₹)17.1713.50+27.2%15.84+8.4%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Standalone net profit rose 27.2% YoY to ₹130.51 crore, faster than consolidated net profit (13.8%). Revenue from operations rose 38.1% to ₹241.88 crore while other income fell 13.8% to ₹51.04 crore.

    Other income is 30.6% of standalone profit before tax of ₹167.05 crore. It includes a ₹15.19 crore dividend from the wholly owned subsidiary Caplin Point Far East Limited. Tax expense rose 38.4% to ₹36.54 crore, 21.9% of profit before tax.

    Inference

    The filing states that the board approved the results on 12 Nov 2026 and that the statutory auditors issued limited review reports, with other auditors covering five subsidiaries and eight step-down subsidiaries. The filing records a final dividend of ₹4.00 per share, paid on 7 Oct 2026, bringing the FY 2025-26 total to ₹8.00 per share.

    The filing does not say why tax expense and finance costs rose, or whether the Mexico and distribution-company acquisitions under due diligence will proceed.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts